Approach to the Patient with Lipid Disorders

  • Kelsey Michiko Shikuma Lee
  • Hussein YassineEmail author


Disorders of lipid metabolism have and continue to be a focal point of research and treatment due to their well-known connection with cardiovascular disease (CVD) and atherosclerosis. Hypertriglyceridemia, in contrast to elevated low density lipoprotein (LDL-C) levels and low levels of high density lipoprotein (HDL), has had a more tenuous relationship as a true independent risk of future CVD events. Although the association between elevated triglyceride (TG) levels and CAD is one of long standing the absolute contribution as a CVD risk factor has been modest or confounded by other lipoprotein parameters. In this chapter, we present a pragmatic approach to the patient at risk of cardiovascular disease, distinguishing lipid disorders that confer an increased CVD risk.


Cholesteryl ester transfer protein (CETP) Coronary artery disease (CAD) High density lipoprotein (HDL) Intermediate density lipoproteins (IDL) Lipoprotein lipase (LPL) Low density lipoprotein (LDL) Nuclear magnetic resonance (NMR) Triglycerides (TG) Verticle auto profile (VAP) Very low density lipoprotein (VLDL) 


  1. 1.
    Bakerman S. ABC’s of interpretive laboratory data, 4th Edn. Scottsdale: Interpretive Laboratory Data, Inc.; 2002.Google Scholar
  2. 2.
    Ochei J. Medical laboratory science theory and practice. New Delhi: Tata McGraw-Hill; 2008.Google Scholar
  3. 3.
    McPherson RA, Pincus MR. Henry’s clinical diagnosis and management by laboratory methods. Philadelphia: Elsevier Health Sciences; 2011.Google Scholar
  4. 4.
    Ensign W. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem. 2009;52(9):1722–7.CrossRefGoogle Scholar
  5. 5.
    Mora S. Are advanced lipoprotein testing and subfractionation clinically useful? Circulation. 2009;119:2396–404.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Brunzell JD. Hypertriglyceridemia. N Engl J Med. 2007;357(10):1009–17.CrossRefPubMedGoogle Scholar
  7. 7.
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics–2014 update: a report from the american heart association. Circulation. 2014;129(3):e28–292. (PubMed PMID: 24352519. Epub 2013/12/20. eng).CrossRefPubMedGoogle Scholar
  8. 8.
    Ferrier DR. Lippincott’s illustrated reviews: biochemistry 6th edn. Baltimore: Lippincott Williams & Wilkins; 2014.Google Scholar
  9. 9.
    Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85(6):2025–33. (PubMed PMID: 1534286. Epub 1992/06/11. eng).CrossRefPubMedGoogle Scholar
  10. 10.
    Murphy MJ, Sheng X, MacDonald TM, Wei L Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med. 2013;173(2):162–4. (PubMed PMID: 23183821. Epub 2012/11/28. eng).CrossRefPubMedGoogle Scholar
  11. 11.
    National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421. (PubMed PMID: 12485966. Epub 2002/12/18. eng).Google Scholar
  12. 12.
    Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2011;123(20):2292–333. (PubMed PMID: 21502576. Epub 2011/04/20. Eng).CrossRefPubMedGoogle Scholar
  13. 13.
    Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Stalenhoef A. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab. 2013;28:423–37.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang F, et al. Thyroid stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones. J Clin Endocrinol Metab. 2012;8(97):2724–31.CrossRefGoogle Scholar
  15. 15.
    Herbst KL, Tannock LR, Deeb SS, Purnell JQ, Brunzell JD, Chait A. Kobberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care. 2003;26(6):1819–24. (PubMed PMID: 12766116. Epub 2003/05/27. eng).CrossRefPubMedGoogle Scholar
  16. 16.
    Manner IW, Baekken M, Oektedalen O, Kvale D, Nowak P, Nielsen SD, et al. Plasma lipopolysaccharide and triglycerides are independently associated and both markers correlate with the development of metabolic syndrome in HIV infection. J Acquir Immune Defic Syndr. 2014;65(4):e158–61. (PubMed PMID: 24577189. Epub 2014/03/01. eng).CrossRefPubMedGoogle Scholar
  17. 17.
    Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. The Lancet. 1998;351(9119):1881–3. (PubMed PMID: 9652687. Epub 1998/07/04. eng).CrossRefGoogle Scholar
  18. 18.
    Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams textbook of endocrinology: expert consult. Philadelphia: Elsevier Health Sciences; 2011.Google Scholar
  19. 19.
    Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu C-Y, et al. Abdominal visceral and subcutaneous adipose tissue compartments association with metabolic risk factors in the Framingham heart study. Circulation. 2007;116(1):39–48.CrossRefPubMedGoogle Scholar
  20. 20.
    Sharma R, Prudente S, Andreozzi F, Powers C, Mannino G, Bacci S, et al. The type 2 diabetes and insulin-resistance locus near IRS1 is a determinant of HDL cholesterol and triglycerides levels among diabetic subjects. Atherosclerosis. 2011;216(1):157–60. (PubMed PMID: 21353221. Pubmed Central PMCID: PMC3089704. Epub 2011/03/01. eng).CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Johansen CT, Kathiresan S, Hegele RA. Genetic determinants of plasma triglycerides. J Lipid Res. 2011;52(2):189–206.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Sparks JD, Sparks CE. Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta. 1994;1215(1–2):9–32. (PubMed PMID: 7948013. Epub 1994/11/17. eng).CrossRefPubMedGoogle Scholar
  23. 23.
    Florez H, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Castillo-Florez S, Lee D, et al. Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. Atherosclerosis. 2006;188(1):134–41. (PubMed PMID: 16298371. Epub 2005/11/22. eng).CrossRefPubMedGoogle Scholar
  24. 24.
    Kwiterovich PO Jr. Diagnosis and management of familial dyslipoproteinemias. Curr Cardiol Rep. 2013;15(6):371. (PubMed PMID: 23666884. Epub 2013/05/15. eng).CrossRefPubMedGoogle Scholar
  25. 25.
    Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299(21):2524–32.CrossRefPubMedGoogle Scholar
  26. 26.
    Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet. 2012;380(9841):572–80.CrossRefGoogle Scholar
  27. 27.
    Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol. 2008;19(4):369–77. (PubMed PMID: 18607184. Epub 2008/07/09. eng).CrossRefPubMedGoogle Scholar
  28. 28.
    U.S. Preventive Services Task Force. Lipid Disorders in Adults (Cholesterol, Dyslipidemia): Screening. Release Date: June 2008. Accessed 5 Dec 2014.
  29. 29.
    Ray KK, Kastelein JJ, Matthijs Boekholdt S, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35(15):960–8. (PubMed PMID: 24639424. Epub 2014/03/19. eng).CrossRefPubMedGoogle Scholar
  30. 30.
    Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–934.CrossRefPubMedGoogle Scholar
  31. 31.
    de Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Clin Pract Endocrinol Metab. 2008;4(11):608–18.CrossRefPubMedGoogle Scholar
  32. 32.
    Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvänne T, Hurme R, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2013;99(1):E45–52.CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Lung NH, Institute B. others. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128:S213–56.CrossRefGoogle Scholar
  34. 34.
    Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317(20):1237–45.CrossRefPubMedGoogle Scholar
  35. 35.
    Robins SJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events VA-HIT: a randomized controlled trial. JAMA. 2001;285(12):1585–91.CrossRefPubMedGoogle Scholar
  36. 36.
    Tonkin AM, et al. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:850–2.CrossRefPubMedGoogle Scholar
  37. 37.
    Fortson MR, et al. Clinical assessment of hyperlipidemia pancreatitis. Am J Gastronenterol. 1995;90(12):2134–9.Google Scholar
  38. 38.
    Yang F, et al. The role of free fatty acids, pancreatic lipase and calcium signalling in injury of isolated acinar cells and pancreatitis model in lipoprotien lipase deficient mice. Acta Physiol (Oxf). 2009;195(1):13–28.CrossRefGoogle Scholar
  39. 39.
    Navina S, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatiti sin obesity. Sci Transl Med. 2011;3(107):107ra110.CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence. J Clin Lipidol. 2012;6(5):413–26. (PubMed PMID: 23009777. Epub 2012/09/27. eng).CrossRefPubMedGoogle Scholar
  41. 41.
    Ginsberg HN, Zhang Y-L, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36(3):232–40.CrossRefPubMedGoogle Scholar
  42. 42.
    Keaney JF, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med. 2014;370(3):275–8. (PubMed PMID: 24283199).CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.LAC+USC Medical CenterLos AngelesUSA
  2. 2.University of Southern CaliforniaLos AngelesUSA

Personalised recommendations